Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Gemcitabine/Carboplatin	417
Overall Study	STARTED	Paclitaxel/Carboplatin	414
Overall Study	Received Induction Therapy	Gemcitabine/Carboplatin	411
Overall Study	Received Induction Therapy	Paclitaxel/Carboplatin	409
Overall Study	Received Consolidation Therapy	Gemcitabine/Carboplatin	169
Overall Study	Received Consolidation Therapy	Paclitaxel/Carboplatin	183
Overall Study	Received Crossover Therapy	Gemcitabine/Carboplatin	77
Overall Study	Received Crossover Therapy	Paclitaxel/Carboplatin	78
Overall Study	COMPLETED	Gemcitabine/Carboplatin	246
Overall Study	COMPLETED	Paclitaxel/Carboplatin	261
Overall Study	NOT COMPLETED	Gemcitabine/Carboplatin	171
Overall Study	NOT COMPLETED	Paclitaxel/Carboplatin	153

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00191646/flow